



46TH ANNUAL EDUCATIONAL CONFERENCE



COLLABORATE. EDUCATE. ADVOCATE.

Atrial Fibrillation Management in Hispanic Adults
Tania Borja-Rodriguez PhD, RN, FNP-BC, AAC

Table of Contents

1. Background
2. Literature Review
3. Purpose and Aims
4. Methods
5. Results
6. Discussion
7. References

Background

- AF mentioned on 183,321 death certificates and found as the underlying cause of death in 26,535 Americans (CDC, 2022).
- > 454,000 hospitalizations with AF as the primary diagnosis (Benjamin et al., 2019).
- AF causes ~1 in 7 strokes and contributes to ~158,000 deaths each year (CDC, 2022).
- Ethnic and race findings indicate an increased AF diagnosis in Whites compared to racial and ethnic minorities (Tamirisa et al., 2021; Wyse et al., 2002).
- Research is warranted to facilitate adoption of and maintenance of AF screening programs, prevention and management in minority adults living in the US specifically in South Bay area of Northern California.

The Health Equity Framework

- Demographics (race, ethnicity, gender, & age)
- Symptoms (AFEQT)
- Comorbidities (type of diagnosis)




Figure 2. Adapted from *The Health Equity Framework: a science and justice-based model for public health researchers and practitioner* by Peterson et al., 2020, *Health Promotion Practice*, 22(6) p.743. doi:10.1177/1524839920950730

Literature Review

AF
Hispanics
Race
Vulnerability




Figure: [National Center for Chronic Disease Prevention and Health Promotion , Division for Heart Disease and Stroke Prevention \(2022\)](#)

Purpose and Aims

Purpose: to explore the SDOH, select sociodemographic and symptom burden in Hispanic/Latino adults compared to non-Hispanics who obtain treatment

Aim 1: Describe sociodemographic, clinical characteristics, SDOH and AF management

Aim 2: Examine associations among sociodemographic, clinical characteristics, SDOH and AF management

Aim 3: Analyze the type of treatment received among Hispanics and non-Hispanics

Methods

- Design
 - Cross-sectional
- Data Source
 - EHR
- Data Collection
 - Retrospective June 2020 – June 2022
- Human Subjects
- Study Variables

Methods

AIM 1 Frequencies, percentages

AIM 2 Bivariate analysis

AIM 3 Logistic regression

Race	n	%
White	441	58.8
Black, African American	7	0.9
Asian	40	5.3
American Indian	2	0.3
Other	260	34.7

Ethnicity	n	%
Hispanic	289	38.8
Not Hispanic	455	61.2

Race-Ethnicity combined	n	%
White, unknown ethnicity	5	0.7
White, Hispanic	32	4.3
White, non-Hispanic	404	53.9
Black, non-Hispanic	7	0.9
Asian, Hispanic	5	0.7
Asian, non-Hispanic	35	4.7
American Indian, Hispanic	2	0.3
Other, unknown ethnicity	1	0.1
Other, Hispanic	250	33.3
Other, non-Hispanic	9	1.2

Race-Ethnicity combined	n	%
White, non-Hispanic	404	53.9
Black, non-Hispanic	7	0.9
Asian, non-Hispanic	35	4.7
Other, non-Hispanic	9	1.2
Hispanic (White, Asian, American Indian, Other)	289	38.5
Other, unknown ethnicity	1	0.1
White, unknown ethnicity	0.7	0.7

Table 1

Sociodemographic and Clinical Characteristics, Social Determinants of Health, and Symptom Burden of Study Population Overall and by Ethnicity (N = 750)†

Characteristic	Overall		Hispanic		Non-Hispanic		χ^2	p
	n	%	n	%	n	%		
Gender							451.90	<.001 ^f
Male	370	49.3	0	0.0	365	100.0		
Female	380	50.7	289	76.3	90	23.7		
Race							649.63	<.001
White	441	58.8	32	7.3	404	92.7		
Black, African American	7	0.9	0	0.0	7	100.0		
Asian	40	5.3	5	12.5	35	87.5		
American Indian	2	0.3	2	100.0	0	0.0		
Other race	260	34.7	250	96.5	9	3.5		
Ethnicity ^a							--	--
Hispanic, Latino (White, Asian, American Indian Other)	289	38.8	--	--	--	--		
Non-Hispanic, non-Latino (White, Black, Asian, Other)	455	61.2	--	--	--	--		
Insurance							58.05	<.001
Medicare	450	60.0	130	29.2	315	70.8		
MediCal	27	3.6	23	85.2	4	14.8		
Private	260	34.7	127	49.0	132	51.0		
Other insurance ^b	13	1.7	9	69.2	4	30.8		

Chi Square

Characteristic	Yes		No		χ^2	p
	n	%	n	%		
Prior AF Surgical Ablation					1.08	.298 ^e
Yes	1	50.0	1	50.0		
No	49	6.6	699	93.4		
Cardioversion					18.44	<.001 ^c
Yes	6	35.3	11	64.7		
No	44	6.0	689	94.0		
AF Related Symptoms					35.89	<.001 ^c
Yes	26	18.3	116	81.7		
No	24	3.9	584	96.1		
Activity Limitation					67.48	<.001 ^c
Yes	22	30.1	51	69.9		
No	28	4.1	649	95.9		
Treatment Concerns					244.76	<.001 ^c
Yes	25	73.5	9	26.5		
No	25	3.5	691	96.5		
AFEQT Patient Questionnaire					362.86	<.001 ^c
Yes	28	93.3	2	6.7		
No	22	3.1	698	96.9		
	M	SD	M	SD	t	p
Age, years	69.02	9.04	81.64	11.45	6.12	<.001 ^c
Travel distance to hospital, miles	18.53	24.43	13.26	29.35	-1.23	.220
Body mass index, kg/m ²	31.31	7.71	28.56	7.75	-2.12	.035

Note. ^aOther insurance = Uninsured, self-pay, workers compensation, international insurance.
^bUnemployed = Retired, disabled, student, other not seeking work. Employed = Full-time, part-time, self-employed.
^cResidence type based on the 2020 definition of the US Department of Agriculture (<https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes>). ^dICD-10 Codes: Infectious, parasitic diseases (A00-B99), Neoplasms (C00-D49), Blood, blood-forming organ, immune diseases (D50-D49), Endocrine, nutritional, metabolic diseases (E00-E89), Mental, behavioral, neurodevelopmental diseases (F01-F99), Nervous system diseases (G00-G99), Eye diseases, adnexa (H00-H59), Ear, mastoid process diseases (H60-H95), Circulatory system diseases (I00-I99), Respiratory system diseases (J00-J99), Digestive system diseases (K00-K95), Skin, subcutaneous tissue diseases (L00-L99), Musculoskeletal, connective tissue diseases (M00-M99), Genitourinary system diseases (N00-N99), Congenital malformations, deformations, chromosomal abnormalities (Q00-Q99), Symptoms, signs, abnormal clinical/lab findings (R00-R99), Injury, poisoning, other consequences of external causes (S00-T88), Special purpose codes (i.e., Covid-19, U00-U85), Factors influencing health status, contact with health services (Z00-Z99). ^ep-value is Fisher's Exact tests, unless otherwise specified ^fYate's Continuity Correction Sig. (2-sided). ^gMonte Carlo Sig. (2-sided). ^hUnequal sample sizes and variances; t-test performed with a random sample of largest group, equal to smallest group (N = 100).

Characteristic	Overall		Hispanic		Non-Hispanic		χ^2	p
	n	%	n	%	n	%		
AF Classification							3.57	.471
Chronic unspecified AF	75	10.0	27	36.0	48	64.0		
Long-standing persistent AF	9	1.2	1	11.1	8	88.9		
Other persistent AF	71	9.5	30	42.9	40	57.1		
Permanent AF	284	37.9	111	39.5	170	60.5		
AF unspecified	311	41.5	120	38.8	189	61.2		
AF Related Symptoms							10.31	.001 ^f
Yes	142	18.9	72	51.1	69	48.9		
No	608	81.1	217	36.0	386	64.0		
Activity Limitation							5.35	.021 ^f
Yes	73	9.7	38	52.1	35	47.9		
No	677	90.3	251	37.4	420	62.6		
Treatment Concerns							1.41	.236 ^f
Yes	34	4.5	17	50.0	17	50.0		
No	716	95.5	272	38.3	438	61.7		
AFEQT Patient Questionnaire							0.11	.746 ^f
Yes	30	4.0	13	43.3	17	56.7		
No	720	96.0	276	38.7	438	61.3		
In-hospital Antiarrhythmic Drugs							2.41	.121 ^f
Yes	146	19.5	65	44.8	80	55.2		
No	604	80.5	224	37.4	375	62.6		



46TH ANNUAL EDUCATIONAL CONFERENCE

Logistic Regression

Table 7

Summary of Logistic Regression Analysis Predicting Patient Prior Catheter Ablation (N = 750)

Variable	<i>B</i>	<i>SE</i>	<i>OR</i>	99% CI		<i>Wald statistic</i>	<i>p</i>
				Lower	Upper		
Ethnicity: Hispanic, Latino	1.29	0.47	3.62	1.44	9.13	7.45	.006
Hypertension diagnosis: Yes	-0.72	0.44	0.49	0.20	1.16	2.61	.106
AF related symptoms: Yes	0.27	0.50	1.31	0.50	3.48	0.30	.583
Age	-0.06	0.02	0.94	0.92	0.97	14.64	< .001
Treatment concerns: Yes	4.22	0.59	68.07	21.46	215.94	51.34	< .001

$\chi^2(5) = 133.545, p < .001$
-2 Log likelihood = 233.02. Nagelkerke $R^2 = 42.2\%$

Notes. CI = Confidence interval for odds ratio (OR). *Reference categories:* Ethnicity, Non-Hispanic/Latino; Hypertension diagnosis, No; AF related symptoms, No; Treatment concerns, No.

Discussion

- **Nursing implications:**
 - Equitable care
- **Clinical Practice:**
 - Early screening
- **Education and Policy:**
 - include SDOH
- **Nursing Research:** covariates ethnicity, educations, income to elucidate health inequities for those who must travel longer distance and adjust for necessity



46TH ANNUAL EDUCATIONAL CONFERENCE

References

- Austin, . W. (2017). Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models. *Statistical Methods in Medical Research*, 26(2), 796–808. <https://doi.org/10.1177/0962280214558972>
- Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway C. W., Carson A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., Delling, F. N., Djousse, L., Elkind, M. S. V., Ferguson, J. F., Fornage, M., Jordan, C. L., Khan, S. S., Kissela, B. M., Knutson, K. L., ... Virani, S. S. (2019). Heart disease and stroke statistics—2019 update: A report from the American Heart Association. *Circulation*, 139(10): e56–528. <https://doi.org/10.1161/CIR.0000000000000659>
- Centers for Disease Control and Prevention. (2022). *Atrial fibrillation*. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm
- Centers for Disease Control and Prevention. (2022). *Atrial fibrillation*. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm Centers for Disease Control and Prevention. (2023). *Stroke facts*. <https://www.cdc.gov/stroke/facts.htm>
- Guadamuz, J. S., Wilder, J. R., Mouslim, M. C., Zenk, S. N., Alexander, G. Z., & Qato, D. (2021). Fewer pharmacies in Black and Hispanic/Latino neighborhoods compared with White or diverse neighborhoods, 2007-15. *Health Affairs*, 40(5), 802–811. <https://doi.org/10.1377/hlthaff.2020.01699>
- O'Neal, W.T., Judd, S. E., Limdi, N.A., McIntyre, W. F., Kleindorfer, D. O., Cushman, M., Howard, V. J., Howard, G., & Soliman, E. Z. (2017). Differential impact of risk factors in Blacks and Whites in the development of atrial fibrillation: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Journal of Racial Ethnic Health Disparities*, 4(4), 718–724. <https://doi.org/10.1007/s40615-016-0275-3>

References

- Peduzzi, P., Concato, J., Kemper, E., Holford, T.R., & Feinstein, A.R. (1996). A simulation study of the number of events per variable in logistic regression analysis. *Journal of Clinical Epidemiology*, 49(12), 1373–1379. [https://doi.org/10.1016/S0895-4356\(96\)00236-3](https://doi.org/10.1016/S0895-4356(96)00236-3)
- Tamirisa, K. P., Al-Khatib, S. M., Mohanty, S., Han, J. K., Natale, A., Gupta, D., Russo, A. M., Al-Ahmad, A., Gillis, A. M., & Thomas, K.L. (2021). Review racial and ethnic differences in the Management of atrial fibrillation. *Canadian Journal of Cardiology*, 3(12), S137–S148. <https://doi.org/10.1016/j.cjco.2021.09.004>
- Wyse, D. G., Love, J. C., Yao, Q., Carlson, M.D., Cassidy, P., Greene, L. H., Martins, J. B., Ocampo, C., Raitt, M. H., Schron, E., Stamato, N. J., Olarte, A., & AVID investigators. (2001). Atrial fibrillation: a risk factor for increased mortality- an AVID analysis. *Journal of Interventional Cardiac Electrophysiology*, 5(3), 267–273. <https://doi.org/10.1023/a:1011460631369>
- Wyse D. G., Waldo, A. L., DiMarco, J. P., Domanski, M. J., Rosenberg, Y., Schron, E. B., Kellen, J. C., Greene, H. L., Mickel, M. C., Dalquist, J. E., & Corley, S. D. (2002). A comparison of the rate control and rhythm control in patients with atrial fibrillation. *New England Journal of Medicine*, 347(23), 1834–1840. <https://doi.org/10.1056/NEJMoa021328>